Mabwell announced that its novel B7-H3-targeting ADC, 7MW3711 received an Orphan Drug Designation from the U.S. FDA for treating Small-Cell Lung Cancer

7MW3711 is developed using Mabwell’s IDDC™ platform and consists of a unique antibody molecule, a novel linker, and the payload Mtoxin™ (TOP1i). It targets tumor cell membranes, gets internalized, and releases a cytotoxic drug to induce apoptosis in tumor cells

In animal models, 7MW3711 demonstrated superior tumor-killing effects compared to other ADCs. Safety evaluations in cynomolgus monkeys showed effective control of on-target and off-target toxicities, indicating a favorable safety profile and pharmacokinetic properties

Research results suggest that 7MW3711 possesses clinical differentiation characteristics, indicating a promising future for its development